ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 834

Citrulline-Polyspecific B Cell Antigen Receptors Arising from Somatic Hypermutation within Clades Demonstrate Pathogenicity in Rheumatoid Arthritis

Philip J. Titcombe1,2, Gustaf Wigerblad3, Natalie Sippl3, Na Zhang1, Anna K. Shmagel4, Peter Sahlström5, Yue Jack Zhang1, Laura Barsness Motschenbacher1, Yogita Ghodke-Puranik6, Monika Hansson7, Lena Israelsson5, Timothy B. Niewold8, Lars Klareskog9, Camilla Svensson10, Khaled Amara7, Vivianne Malmström11 and Daniel L. Mueller1, 1Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, 2Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 3Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 4Rheumatic & Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, 5Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 6Colton Center for Autoimmunity, New York University, New York, NY, 7Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 8Rheumatology and Immunology, Mayo Clinic, Rochester, MN, 9Rheumatology unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 10Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, 11Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: antigen RA, B cells, citrulline, immunoglobulin (IG) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: B Cell Biology and Targets in Autoimmune Disease

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Citrulline–modified proteins arising from the post-translational modification of arginine residues are recognized as primary rheumatoid arthritis (RA) autoantigen targets based on the strong association of anti-citrullinated protein antibodies (ACPA) with RA disease development. Nevertheless, the repertoire of citrullinated protein–specific B cell antigen receptors (BCRs) has not previously been directly assessed.

Methods: 89 subjects from the IRB-approved University of Minnesota ACPA+ RA cohort who met the 2010 ACR/EULAR criteria for RA provided blood samples and clinical data for use in this study. Citrullinated filaggrin peptide CFC1 and citrullinated a-enolase peptide CEP-1 were used in the construction of tetramer sets designed to specifically capture and characterize autoreactive citrullinated protein–specific B cells in the unaltered, polyclonal repertoire of RA patients. Citrullinated peptide tetramer–bound B cells were subjected to flow cytometric cell sorting and single cell IGH, IGK, and IGL gene sequencing for B cell lineage determinations. BCR gene sequences were also expressed as recombinant human monoclonal antibodies, and tested for their ability to bind to citrullinated peptides and proteins. Finally, select human V-(D)-J sequences were expressed as recombinant mouse monoclonal antibodies to test their ability to prolong endotoxin-induced arthritis.

Results: Tetramer–binding CFC1– and CEP-1–specific IgD– CD27+ switched-memory B cells were found in increased numbers in the blood of RA subjects who also demonstrated high titers of anti-CFC1 and/or –CEP-1 serum antibodies, respectively (5.7-fold increase for CFC1, Pvalue < 0.01; 5.3-fold increase for CEP-1; Pvalue = 0.01). The frequency of CFC1–specific switched-memory B cells was also positively associated with the duration of disease (p= 0.02), the presence of subcutaneous nodules (p = 0.02), and the DAS28-ESR disease activity index (p = 0.01). Citrullinated peptide tetramer–specific BCRs had highly mutated immunoglobulin (Ig) heavy and light chain complementarity determining region (CDR) sequences, biased V-region gene usage, and conserved CDR3 junction lengths. Parsimonious clustering of related IGH, IGK, and IGL nucleotide sequences demonstrated that the clonal expansion of rare individual B cell lineages occurs in association with progressive amino acid sequence divergence. Recombinant human monoclonal antibodies generated from citrullinated peptide tetramer–sorted B cells within extended clades confirmed target peptide antigen–binding for most clones, yet citrulline–dependent cross-reactivity to a broad set of distinct citrullinated peptides and proteins implicated in RA was also observed. Finally, a pair of citrullinated protein–specific recombinant monoclonal antibodies with cross-reactive autoantigen–binding profiles promoted arthritis in mice.

Conclusion: Broad anti-citrullinated protein antibody specificities in RA may arise from a restricted repertoire of B cell clades with evolving and divergent citrulline–polyspecific BCRs.


Disclosure: P. J. Titcombe, None; G. Wigerblad, None; N. Sippl, None; N. Zhang, None; A. K. Shmagel, None; P. Sahlström, None; Y. J. Zhang, None; L. Barsness Motschenbacher, None; Y. Ghodke-Puranik, None; M. Hansson, None; L. Israelsson, None; T. B. Niewold, EMD Serono and Janssen, Inc, 2; L. Klareskog, None; C. Svensson, None; K. Amara, None; V. Malmström, None; D. L. Mueller, None.

To cite this abstract in AMA style:

Titcombe PJ, Wigerblad G, Sippl N, Zhang N, Shmagel AK, Sahlström P, Zhang YJ, Barsness Motschenbacher L, Ghodke-Puranik Y, Hansson M, Israelsson L, Niewold TB, Klareskog L, Svensson C, Amara K, Malmström V, Mueller DL. Citrulline-Polyspecific B Cell Antigen Receptors Arising from Somatic Hypermutation within Clades Demonstrate Pathogenicity in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/citrulline-polyspecific-b-cell-antigen-receptors-arising-from-somatic-hypermutation-within-clades-demonstrate-pathogenicity-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/citrulline-polyspecific-b-cell-antigen-receptors-arising-from-somatic-hypermutation-within-clades-demonstrate-pathogenicity-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology